Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC
"Qilu is one of the leading pharmaceutical companies with global expertise and capacity in innovative R&D, manufacturing and marketing in China.
- "Qilu is one of the leading pharmaceutical companies with global expertise and capacity in innovative R&D, manufacturing and marketing in China.
- "\nQilu Pharmaceutical is a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines.
- To date, Qilu has launched 200+ products with 30+ products "First to launch" in China and 3 products "D181 launch" in US with approximately US$4.2 billion sales revenue in 2020.
- Peptron is running a GMP manufacturing facility for sustained-release peptide injectables.